Hui Shao, YS Biopharma president and CEO (L) and Yi Zhang, founder and chairman
China’s YishengBio is going to Nasdaq, making the transition via $230M SPAC maneuver
After attempting to make it on the HKEX last year, a Chinese biopharma is finally taking the once-flashy SPAC route to get on the Nasdaq …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
